New hope for pancreatic cancer: targeted drug plus chemo enters early trial
NCT ID NCT06396091
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called zolbetuximab combined with standard chemotherapy for people with a specific type of advanced pancreatic cancer. The drug targets a protein on cancer cells to help the immune system attack the tumor. The main goals are to check safety and find the right dose in about 12 adults who haven't had chemo before.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Experimental drug hopes to boost chemo against tough pancreatic cancer